Group 1 - The core point of the article is that Shan Yu Group Holdings plans to issue up to 41.36 million new shares, representing approximately 16.67% of the enlarged total issued share capital after the placement [1] - The placement price is set at HKD 0.120 per share, which is about 11.11% lower than the closing price of HKD 0.135 on August 14 [1] - The net proceeds from the placement are estimated to be approximately HKD 4.91 million, intended for the company's operational funding [1] Group 2 - On September 3, a shareholder of Shan Yu Group Holdings deposited shares worth HKD 7.0312 million into Baoxin Securities, accounting for 20% of the total [1]

Group 1 - The company GBA Group plans to place a maximum of 46.5669 million shares, representing approximately 16.67% of the enlarged total share capital [1] - The placement price is set at HKD 0.200 per share, which is a discount of 12.66% compared to the closing price of HKD 0.229 on September 3 [1] - If the placement is fully completed, the expected net proceeds will be approximately HKD 8.61 million, which will be used for the company's general working capital and/or the development of new businesses [1]

Core Viewpoint - WuXi AppTec announced a placement agreement with an underwriter to fully underwrite up to 22.277 million shares at a price of HKD 58.85 per share, aiming to raise approximately HKD 1.311 billion in total, with net proceeds of about HKD 1.301 billion [1] Fund Utilization - Approximately 90% of the raised funds will be used to expand the company's service capabilities and production capacity, particularly in the areas of antibody-drug conjugates, active pharmaceutical ingredients, and clinical and commercial production [1] - The remaining approximately 10% of the funds will be allocated for the company's working capital and general corporate purposes [1]

Core Viewpoint - The company, Sihuan Pharmaceutical Holdings Group Ltd (02096), has entered into a placement and subscription agreement to issue 121 million shares at a price of HKD 12.95 per share, aiming to raise approximately HKD 1.567 billion for research and operational needs [1] Group 1 - The seller, Simcere Pharmaceutical Holding Limited, plans to sell 121 million shares through the placement agent at a price of HKD 12.95 per share [1] - The total estimated proceeds from the subscription are approximately HKD 1.567 billion, with a net amount of about HKD 1.5535 billion [1] - Approximately 90% of the proceeds will be allocated for research and development expenses, while around 10% will be used for working capital and other general corporate purposes [1]

Group 1 - The company, ZhongAn Group, announced a placement agreement to issue up to 48.3 million shares, representing approximately 9.3% of the total issued share capital of ZhongAn Technology as of the announcement date [1] - The placement price is set at HKD 3.53 per share, which is about 15.14% lower than the closing price of HKD 4.16 on the date of the agreement [1] - The net proceeds from the placement are estimated to be approximately HKD 168.5 million, intended to strengthen the future development of the company's core business, including investments in new industries and expanding market share [1] Group 2 - ZhongAn Technology is a company listed on the Hong Kong Stock Exchange and is a subsidiary of ZhongAn Group [1] - As of the announcement date, the company indirectly holds approximately 73.4% of the total issued shares of ZhongAn Technology [1] - Upon completion of the placement, assuming all 48.3 million shares are successfully placed, the company's indirect holding in ZhongAn Technology will decrease to approximately 64.1% [1]

假设所有配售股份获悉数配售，配售事项所得款项总额将约为4510万港元，而配售事项所得款项净额 (经扣除配售事项的配售佣金及其他开支后)将约为4400万港元。净价格约为每股配售股份0.576港元。公 司拟按以下方式动用所得款项净额：不少于70%用于扩展集团的产品销售业务;及余下用作集团一般营 运资金。 悟喜生活(08148)发布公告，于2025年8月29日(交易时段后)，公司与配售代理订立配售协议，据此，公 司已有条件同意透过配售代理按竭尽所能基准以每股配售股份0.59港元的配售价配售最多7635.84万股配 售股份予不少于6名承配人，而有关承配人与其最终实益拥有人将为独立第三方。每股配售股份0.59港 元的配售价较股份于最后交易日在联交所所报之收市价每股股份0.73港元折让约19.18%。 ...

悟喜生活(08148)发布公告，于2025年8月29日(交易时段后)，公司与配售代理订立配售协议，据此，公 司已有条件同意透过配售代理按竭尽所能基准以每股配售股份0.59港元的配售价配售最多7635.84万股配 售股份予不少于6名承配人，而有关承配人与其最终实益拥有人将为独立第三方。每股配售股份0.59港 元的配售价较股份于最后交易日在联交所所报之收市价每股股份0.73港元折让约19.18%。 假设所有配售股份获悉数配售，配售事项所得款项总额将约为4510万港元，而配售事项所得款项净额 (经扣除配售事项的配售佣金及其他开支后)将约为4400万港元。净价格约为每股配售股份0.576港元。公 司拟按以下方式动用所得款项净额：不少于70%用于扩展集团的产品销售业务;及余下用作集团一般营 运资金。 ...

配售事项所得款项净额估计约为港币1.307亿元。 裕承科金(00279)发布公告，于2025年8月29日(交易时段后)，公司与配售代理订立配售协议，据此，公 司同意透过配售代理按尽力基准以配售价每股配售股份港币0.690元向不少于六名承配人配售最多1.91亿 股配售股份。 配售价较于2025年8月29日(即配售协议日期)在联交所所报收市价每股股份港币0.850元折让约18.8%。 ...

募集资金将用于：产品研发与升级，提升技术和解决方案能力。产品商业化及业务发展，加强外部合作 以扩大公司规模和市场份额。潜在的收购投资、人才吸引、营运资金补充及一般公司用途。 晶泰控股公布，公司已与配售代理签订配售协议，计划以每股9.28港元的配售价，配售最多约2.86亿股 股份。若配售成功，公司预计净筹约26.3亿港元。 （文章来源：证券时报网） ...

Core Viewpoint - The company, 科笛-B (02487), has announced a share placement agreement to issue approximately 28.9 million shares at a price of HKD 8.40 per share, representing about 9.05% of its existing shares, with the net proceeds expected to be around HKD 240 million [1] Group 1: Share Placement Details - The placement price of HKD 8.40 per share reflects a discount of approximately 12.04% compared to the closing price of HKD 9.55 on the announcement date [1] - The share placement is facilitated by placement agents who will act on behalf of the company [1] Group 2: Use of Proceeds - Approximately 45% of the net proceeds will be allocated for clinical research and trials related to local fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% of the net proceeds will be used for marketing activities, channel expansion, and brand building for CU-40102 (a topical finasteride spray) and CU-10201 (a topical 4% minocycline foam) [1] - The remaining 10% of the net proceeds will be utilized for working capital and other general corporate purposes [1]